<\/p>\n
Vymada<\/strong> \u03b5\u03af\u03bd\u03b1\u03b9 50 \u03ba\u03b1\u03b9 100 mg sacubitril\/valsartan<\/strong> \u03b4\u03b9\u03c3\u03ba\u03af\u03b1 \u03b1\u03c0\u03cc \u03c4\u03b7 Novartis \u2014 \u03ad\u03bd\u03b1\u03c2 \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1\u03c2 \u03c4\u03bf\u03c5 \u03c5\u03c0\u03bf\u03b4\u03bf\u03c7\u03ad\u03b1 \u03c4\u03b7\u03c2 \u03b1\u03b3\u03b3\u03b5\u03b9\u03bf\u03c4\u03b5\u03bd\u03c3\u03af\u03bd\u03b7\u03c2-\u03bd\u03b5\u03c0\u03c1\u03b9\u03bb\u03c5\u03c3\u03af\u03bd\u03b7 (ARNI)<\/strong>. \u03a4\u03bf \u03c3\u03c5\u03c3\u03c4\u03b1\u03c4\u03b9\u03ba\u03cc sacubitril \u03b1\u03bd\u03b1\u03c3\u03c4\u03ad\u03bb\u03bb\u03b5\u03b9 \u03c4\u03b7 \u03bd\u03b5\u03c0\u03c1\u03b9\u03bb\u03c5\u03c3\u03af\u03bd\u03b7 (\u03ad\u03bd\u03b1 \u03ad\u03bd\u03b6\u03c5\u03bc\u03bf \u03c0\u03bf\u03c5 \u03b4\u03b9\u03b1\u03c3\u03c0\u03ac \u03c4\u03b1 \u03bdatriuretic \u03c0\u03b5\u03c0\u03c4\u03af\u03b4\u03b9\u03b1, \u03c4\u03b7 \u03b2\u03c1\u03b1\u03b4\u03c5\u03ba\u03b9\u03bd\u03af\u03bd\u03b7 \u03ba\u03b1\u03b9 \u03c4\u03b7\u03bd \u03b1\u03b4\u03c1\u03b5\u03bd\u03bf\u03bc\u03b5\u03b4\u03bf\u03c5\u03bb\u03af\u03bd\u03b7), \u03b5\u03bd\u03b9\u03c3\u03c7\u03cd\u03bf\u03bd\u03c4\u03b1\u03c2 \u03c4\u03b7\u03bd \u03c9\u03c6\u03ad\u03bb\u03b9\u03bc\u03b7 \u03b1\u03b3\u03b3\u03b5\u03b9\u03bf\u03b4\u03b9\u03b1\u03c3\u03c4\u03b1\u03bb\u03c4\u03b9\u03ba\u03ae \u03ba\u03b1\u03b9 \u03bdatriuretic \u03bf\u03b4\u03cc\u00b7 \u03c4\u03bf \u03c3\u03c5\u03c3\u03c4\u03b1\u03c4\u03b9\u03ba\u03cc valsartan \u03bc\u03c0\u03bb\u03bf\u03ba\u03ac\u03c1\u03b5\u03b9 \u03c4\u03bf\u03bd \u03c5\u03c0\u03bf\u03b4\u03bf\u03c7\u03ad\u03b1 \u03c4\u03b7\u03c2 \u03b1\u03b3\u03b3\u03b5\u03b9\u03bf\u03c4\u03b5\u03bd\u03c3\u03af\u03bd\u03b7\u03c2-II, \u03b1\u03c0\u03bf\u03c4\u03c1\u03ad\u03c0\u03bf\u03bd\u03c4\u03b1\u03c2 \u03c4\u03b7 \u03c3\u03c5\u03c3\u03c4\u03bf\u03bb\u03ae \u03c4\u03c9\u03bd \u03b1\u03b3\u03b3\u03b5\u03af\u03c9\u03bd \u03ba\u03b1\u03b9 \u03c4\u03b7 \u03b4\u03b9\u03b1\u03c4\u03ae\u03c1\u03b7\u03c3\u03b7 \u03bd\u03b1\u03c4\u03c1\u03af\u03bf\u03c5 \u03c0\u03bf\u03c5 \u03c0\u03c1\u03bf\u03ba\u03b1\u03bb\u03b5\u03af\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03b1\u03bb\u03b4\u03bf\u03c3\u03c4\u03b5\u03c1\u03cc\u03bd\u03b7. \u0391\u03c1\u03c7\u03b9\u03ba\u03ae \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03b3\u03b9\u03b1 HF-REF (EF \u226440%)<\/strong> \u03c3\u03cd\u03bc\u03c6\u03c9\u03bd\u03b1 \u03bc\u03b5 \u03c4\u03b9\u03c2 \u03bf\u03b4\u03b7\u03b3\u03af\u03b5\u03c2 ESC 2021 \u03ba\u03b1\u03b9 AHA\/ACC 2022 \u2014 \u03b1\u03bd\u03c4\u03b9\u03ba\u03b1\u03b8\u03b9\u03c3\u03c4\u03ac \u03c4\u03bf\u03bd \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1 \u03c4\u03b7\u03c2 \u03bc\u03b5\u03c4\u03b1\u03c4\u03c1\u03b5\u03c0\u03c4\u03b9\u03ba\u03ae\u03c2 \u03b5\u03bd\u03b6\u03cd\u03bc\u03bf\u03c5 (ACE) \u03ae \u03c4\u03bf\u03bd ARB \u03c3\u03c4\u03bf\u03c5\u03c2 \u03c0\u03b5\u03c1\u03b9\u03c3\u03c3\u03cc\u03c4\u03b5\u03c1\u03bf\u03c5\u03c2 \u03c3\u03c4\u03b1\u03b8\u03b5\u03c1\u03bf\u03cd\u03c2 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03bc\u03b5 HF-REF (\u03b7 \u03bc\u03b5\u03bb\u03ad\u03c4\u03b7 PARADIGM-HF 2014 \u03ad\u03b4\u03b5\u03b9\u03be\u03b5 20% \u03bc\u03b5\u03b9\u03c9\u03bc\u03ad\u03bd\u03bf \u03ba\u03af\u03bd\u03b4\u03c5\u03bd\u03bf \u03ba\u03b1\u03c1\u03b4\u03b9\u03b1\u03b3\u03b3\u03b5\u03b9\u03b1\u03ba\u03bf\u03cd \u03b8\u03b1\u03bd\u03ac\u03c4\u03bf\u03c5 \u03ae \u03bd\u03bf\u03c3\u03b7\u03bb\u03b5\u03af\u03b1\u03c2 \u03b3\u03b9\u03b1 \u03ba\u03b1\u03c1\u03b4\u03b9\u03b1\u03ba\u03ae \u03b1\u03bd\u03b5\u03c0\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1 \u03c3\u03b5 \u03c3\u03cd\u03b3\u03ba\u03c1\u03b9\u03c3\u03b7 \u03bc\u03b5 \u03c4\u03b7\u03bd \u03b5\u03bd\u03b1\u03bb\u03b1\u03c0\u03c1\u03af\u03bb\u03b7). \u0394\u03cc\u03c3\u03b7: 50 \u03ba\u03b1\u03b9 100 mg \u03b4\u03cd\u03bf \u03c6\u03bf\u03c1\u03ad\u03c2 \u03c4\u03b7\u03bd \u03b7\u03bc\u03ad\u03c1\u03b1\u00b7 \u03c0\u03c1\u03bf\u03c3\u03b1\u03c1\u03bc\u03bf\u03b3\u03ae \u03ba\u03ac\u03b8\u03b5 2-4 \u03b5\u03b2\u03b4\u03bf\u03bc\u03ac\u03b4\u03b5\u03c2 \u03b3\u03b9\u03b1 \u03c3\u03c4\u03cc\u03c7\u03bf 97\/103 mg \u03b4\u03cd\u03bf \u03c6\u03bf\u03c1\u03ad\u03c2 \u03c4\u03b7\u03bd \u03b7\u03bc\u03ad\u03c1\u03b1. \u0391\u03c0\u03bf\u03bb\u03cd\u03c4\u03c9\u03c2 \u03b1\u03bd\u03c4\u03b5\u03bd\u03b4\u03b5\u03b9\u03ba\u03bd\u03cd\u03b5\u03c4\u03b1\u03b9 \u03c3\u03c4\u03b7\u03bd \u03b5\u03b3\u03ba\u03c5\u03bc\u03bf\u03c3\u03cd\u03bd\u03b7, \u03c3\u03b5 \u03b9\u03c3\u03c4\u03bf\u03c1\u03b9\u03ba\u03cc \u03b1\u03b3\u03b3\u03b5\u03b9\u03bf\u03bf\u03af\u03b4\u03b7\u03bc\u03b1 \u03b1\u03c0\u03cc \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03b5\u03af\u03c2 ACE \u03ae ARB, \u03ba\u03b1\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 36 \u03c9\u03c1\u03ce\u03bd \u03b1\u03c0\u03cc \u03bf\u03c0\u03bf\u03b9\u03b1\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03b4\u03cc\u03c3\u03b7 \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1 ACE<\/strong> (\u03b1\u03c0\u03b1\u03b9\u03c4\u03b5\u03af\u03c4\u03b1\u03b9 \u03c0\u03b5\u03c1\u03af\u03bf\u03b4\u03bf\u03c2 \u03b1\u03c0\u03bf\u03c7\u03ae\u03c2 \u03b3\u03b9\u03b1 \u03c4\u03b7\u03bd \u03b1\u03c0\u03bf\u03c6\u03c5\u03b3\u03ae \u03b1\u03b3\u03b3\u03b5\u03b9\u03bf\u03bf\u03af\u03b4\u03b7\u03bc\u03b1).<\/p>\n<\/div>\n \ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n \u03a4\u03b1 \u03b3\u03b5\u03bd\u03cc\u03c3\u03b7\u03bc\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03ac \u03bc\u03b1\u03c2 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd WHO-GMP \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae, \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u2014 \u03c7\u03c9\u03c1\u03af\u03c2 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b5\u03be\u03c9\u03c4\u03b5\u03c1\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b4\u03ad\u03bc\u03b1\u03c4\u03bf\u03c2. \u039f\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u03b4\u03c1\u03bf\u03bc\u03bf\u03bb\u03bf\u03b3\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae (\u03bf\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ad\u03c2 \u03b5\u03ba\u03ba\u03b1\u03b8\u03ac\u03c1\u03b9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u2014 \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5). \u0393\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b4\u03b5\u03ba\u03c4\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03c1\u03c5\u03c0\u03c4\u03bf\u03bd\u03bf\u03bc\u03af\u03c3\u03bc\u03b1\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03b1\u03c0\u03b5\u03b6\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ac SEPA. \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u0395\u03be\u03b1\u03c3\u03c6\u03b1\u03bb\u03af\u03c3\u03b5\u03ce\u03c2 \u03bc\u03b1\u03c2.<\/p>\n \u03a4\u03bf Vymada \u03b5\u03af\u03bd\u03b1\u03b9 \u03b4\u03b9\u03c3\u03ba\u03af\u03b1 \u03c3\u03b1\u03ba\u03bf\u03c5\u03bc\u03c0\u03b9\u03c4\u03c1\u03af\u03bb\/\u03b2\u03b1\u03bb\u03c3\u03b1\u03c1\u03c4\u03ac\u03bd\u03b7\u03c2 50 \u03ba\u03b1\u03b9 100 mg \u03b1\u03c0\u03cc \u03c4\u03b7 Novartis, \u03b4\u03b9\u03b1\u03b8\u03ad\u03c3\u03b9\u03bc\u03b1 \u03c3\u03b5 \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b5\u03c2 28-84 \u03b4\u03b9\u03c3\u03ba\u03af\u03c9\u03bd. \u0391\u03c1\u03c7\u03b9\u03ba\u03ac \u03ba\u03c5\u03ba\u03bb\u03bf\u03c6\u03cc\u03c1\u03b7\u03c3\u03b5 \u03c9\u03c2 Novartis Entresto (2015)\u00b7 \u03b5\u03af\u03bd\u03b1\u03b9 \u03bf \u03c0\u03c1\u03ce\u03c4\u03bf\u03c2 \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1\u03c2 \u03c5\u03c0\u03bf\u03b4\u03bf\u03c7\u03ad\u03c9\u03bd \u03b1\u03b3\u03b3\u03b5\u03b9\u03bf\u03c4\u03b5\u03bd\u03c3\u03af\u03bd\u03b7\u03c2-\u03bd\u03b5\u03c0\u03c1\u03b9\u03bb\u03c5\u03c3\u03af\u03bd\u03b7\u03c2 (ARNI).<\/p>\n \u0394\u03cd\u03bf \u03c3\u03c5\u03bc\u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03b1\u03c4\u03b9\u03ba\u03bf\u03af \u03bc\u03b7\u03c7\u03b1\u03bd\u03b9\u03c3\u03bc\u03bf\u03af:<\/p>\n PARADIGM-HF (2014)<\/strong> \u2014 8.442 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03bc\u03b5 HF-REF (EF \u226440%) \u03c0\u03bf\u03c5 \u03ae\u03b4\u03b7 \u03ad\u03bb\u03b1\u03b2\u03b1\u03bd \u03b2\u03ad\u03bb\u03c4\u03b9\u03c3\u03c4\u03b7 \u03c6\u03b1\u03c1\u03bc\u03b1\u03ba\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u03b1\u03b3\u03c9\u03b3\u03ae \u03c4\u03c5\u03c7\u03b1\u03b9\u03bf\u03c0\u03bf\u03b9\u03ae\u03b8\u03b7\u03ba\u03b1\u03bd \u03c3\u03b5 \u03c3\u03b1\u03ba\u03bf\u03c5\u03bc\u03c0\u03b9\u03c4\u03c1\u03af\u03bb\/\u03b2\u03b1\u03bb\u03c3\u03b1\u03c1\u03c4\u03ac\u03bd\u03b7 \u03ae \u03b5\u03bd\u03ac\u03bb\u03b1\u03c0\u03c1\u03b9\u03bb 10 mg bd. \u0394\u03b9\u03b1\u03ba\u03cc\u03c0\u03b7\u03ba\u03b5 \u03c0\u03c1\u03cc\u03c9\u03c1\u03b1 \u03bb\u03cc\u03b3\u03c9 \u03bf\u03c6\u03ad\u03bb\u03bf\u03c5\u03c2: 20% \u03bc\u03b5\u03af\u03c9\u03c3\u03b7 \u03c4\u03b7\u03c2 \u03ba\u03b1\u03c1\u03b4\u03b9\u03b1\u03ba\u03ae\u03c2 \u03b8\u03bd\u03b7\u03c3\u03b9\u03bc\u03cc\u03c4\u03b7\u03c4\u03b1\u03c2 \u03ae \u03bd\u03bf\u03c3\u03b7\u03bb\u03b5\u03af\u03b1\u03c2 \u03bb\u03cc\u03b3\u03c9 \u03ba\u03b1\u03c1\u03b4\u03b9\u03b1\u03ba\u03ae\u03c2 \u03b1\u03bd\u03b5\u03c0\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1\u03c2<\/strong> (\u03c0\u03c1\u03c9\u03c4\u03b1\u03c1\u03c7\u03b9\u03ba\u03cc \u03c4\u03b5\u03bb\u03b9\u03ba\u03cc \u03c3\u03b7\u03bc\u03b5\u03af\u03bf), 16% \u03bc\u03b5\u03af\u03c9\u03c3\u03b7 \u03c4\u03b7\u03c2 \u03c3\u03c5\u03bd\u03bf\u03bb\u03b9\u03ba\u03ae\u03c2 \u03b8\u03bd\u03b7\u03c3\u03b9\u03bc\u03cc\u03c4\u03b7\u03c4\u03b1\u03c2. \u0391\u03c5\u03c4\u03ae \u03ae\u03c4\u03b1\u03bd \u03b7 \u03c0\u03c1\u03ce\u03c4\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03c0\u03bf\u03c5 \u03be\u03b5\u03c0\u03ad\u03c1\u03b1\u03c3\u03b5 \u03ad\u03bd\u03b1\u03bd \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1 ACE \u03c0\u03bb\u03ae\u03c1\u03bf\u03c5\u03c2 \u03b4\u03cc\u03c3\u03b7\u03c2 \u03c3\u03b5 \u03ac\u03bc\u03b5\u03c3\u03b7 \u03c3\u03cd\u03b3\u03ba\u03c1\u03b9\u03c3\u03b7 \u03c3\u03b5 HF-REF. \u039a\u03b1\u03b8\u03b9\u03ad\u03c1\u03c9\u03c3\u03b5 \u03c4\u03bf ARNI \u03c9\u03c2 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03c0\u03c1\u03ce\u03c4\u03b7\u03c2 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ae\u03c2 \u03b3\u03b9\u03b1 HF-REF \u03c3\u03c4\u03b9\u03c2 \u03bf\u03b4\u03b7\u03b3\u03af\u03b5\u03c2 \u03b1\u03c0\u03cc \u03c4\u03bf 2016.<\/p>\n PARAGON-HF (2019)<\/strong> \u2014 4,822 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03bc\u03b5 \u03ba\u03b1\u03c1\u03b4\u03b9\u03b1\u03ba\u03ae \u03b1\u03bd\u03b5\u03c0\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1 \u03bc\u03b5 \u03b4\u03b9\u03b1\u03c4\u03b7\u03c1\u03b7\u03bc\u03ad\u03bd\u03bf \u03ba\u03bb\u03ac\u03c3\u03bc\u03b1 \u03b5\u03be\u03ce\u03b8\u03b7\u03c3\u03b7\u03c2 (HF-PEF, EF \u226545%); \u03b4\u03b5\u03bd \u03ad\u03c6\u03c4\u03b1\u03c3\u03b5 \u03c4\u03bf \u03c0\u03c1\u03c9\u03c4\u03b1\u03c1\u03c7\u03b9\u03ba\u03cc \u03c4\u03b5\u03bb\u03b9\u03ba\u03cc \u03c3\u03b7\u03bc\u03b5\u03af\u03bf (13% \u03bc\u03b5\u03af\u03c9\u03c3\u03b7, p=0,06), \u03b1\u03bb\u03bb\u03ac \u03c0\u03b1\u03c1\u03bf\u03c5\u03c3\u03af\u03b1\u03c3\u03b5 \u03cc\u03c6\u03b5\u03bb\u03bf\u03c2 \u03c3\u03c4\u03b7\u03bd \u03c5\u03c0\u03bf\u03bf\u03bc\u03ac\u03b4\u03b1 \u03bc\u03b5 EF 45-57%. \u0397 FDA \u03b5\u03bd\u03ad\u03ba\u03c1\u03b9\u03bd\u03b5 \u03ad\u03bd\u03b1 \u03b5\u03c5\u03c1\u03cd\u03c4\u03b5\u03c1\u03bf \u03b5\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2 \u03b3\u03b9\u03b1 \u03ba\u03b1\u03c1\u03b4\u03b9\u03b1\u03ba\u03ae \u03b1\u03bd\u03b5\u03c0\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1 \u03c4\u03bf 2021, \u03c3\u03c5\u03bc\u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03b1\u03bd\u03bf\u03bc\u03ad\u03bd\u03b7\u03c2 \u03c4\u03b7\u03c2 HF-PEF\u00b7 \u03bf\u03b9 \u03bf\u03b4\u03b7\u03b3\u03af\u03b5\u03c2 \u03c4\u03bf\u03c0\u03bf\u03b8\u03b5\u03c4\u03bf\u03cd\u03bd \u03c0\u03b9\u03bf \u03c0\u03c1\u03bf\u03c3\u03b5\u03ba\u03c4\u03b9\u03ba\u03ac \u03c4\u03bf ARNI \u03c3\u03c4\u03b7\u03bd HF-PEF \u03cc\u03c4\u03b1\u03bd \u03c4\u03bf EF \u03b5\u03af\u03bd\u03b1\u03b9 \u03bc\u03ad\u03c4\u03c1\u03b9\u03b1 \u03bc\u03b5\u03b9\u03c9\u03bc\u03ad\u03bd\u03bf.<\/p>\n TRANSITION \u03ba\u03b1\u03b9 PIONEER-HF (2019)<\/strong> \u2014 \u03b7 \u03ad\u03bd\u03b1\u03c1\u03be\u03b7 \u03c4\u03bf\u03c5 ARNI \u03ba\u03b1\u03c4\u03ac \u03c4\u03b7 \u03b4\u03b9\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1 \u03bf\u03be\u03b5\u03af\u03b1\u03c2 \u03bd\u03bf\u03c3\u03b7\u03bb\u03b5\u03af\u03b1\u03c2 \u03b3\u03b9\u03b1 \u03ba\u03b1\u03c1\u03b4\u03b9\u03b1\u03ba\u03ae \u03b1\u03bd\u03b5\u03c0\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1 \u03b5\u03af\u03bd\u03b1\u03b9 \u03b1\u03c3\u03c6\u03b1\u03bb\u03ae\u03c2 \u03ba\u03b1\u03b9 \u03bf\u03b4\u03b7\u03b3\u03b5\u03af \u03c3\u03b5 \u03bc\u03b5\u03b3\u03b1\u03bb\u03cd\u03c4\u03b5\u03c1\u03b7 \u03bc\u03b5\u03af\u03c9\u03c3\u03b7 \u03c4\u03bf\u03c5 NT-proBNP \u03c3\u03b5 \u03c3\u03cd\u03b3\u03ba\u03c1\u03b9\u03c3\u03b7 \u03bc\u03b5 \u03c4\u03b7\u03bd \u03bc\u03b5\u03c4\u03b1\u03b3\u03b5\u03bd\u03ad\u03c3\u03c4\u03b5\u03c1\u03b7 \u03b1\u03bb\u03bb\u03b1\u03b3\u03ae.<\/p>\n \u0394\u03b9\u03b1\u03b8\u03ad\u03c3\u03b9\u03bc\u03b5\u03c2 \u03b4\u03cc\u03c3\u03b5\u03b9\u03c2 (mg sacubitril \/ mg valsartan):<\/p>\n \u03a4\u03c5\u03c0\u03b9\u03ba\u03ae \u03c4\u03b9\u03c4\u03bb\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7:<\/strong> \u03be\u03b5\u03ba\u03b9\u03bd\u03ae\u03c3\u03c4\u03b5 \u03bc\u03b5 49\/51 mg \u03b4\u03cd\u03bf \u03c6\u03bf\u03c1\u03ad\u03c2 \u03b7\u03bc\u03b5\u03c1\u03b7\u03c3\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03c3\u03c4\u03b1\u03b8\u03b5\u03c1\u03bf\u03cd\u03c2 \u03c3\u03b5 \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03b5\u03af\u03c2 ACE \u03ae ARB\u00b7 \u03be\u03b5\u03ba\u03b9\u03bd\u03ae\u03c3\u03c4\u03b5 \u03bc\u03b5 24\/26 mg \u03b4\u03cd\u03bf \u03c6\u03bf\u03c1\u03ad\u03c2 \u03b7\u03bc\u03b5\u03c1\u03b7\u03c3\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03c0\u03bf\u03c5 \u03b4\u03b5\u03bd \u03ad\u03c7\u03bf\u03c5\u03bd \u03bb\u03ac\u03b2\u03b5\u03b9 \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03b5\u03af\u03c2 ACE, \u03bc\u03b5 \u03c7\u03b1\u03bc\u03b7\u03bb\u03ae \u03c0\u03af\u03b5\u03c3\u03b7, \u03bd\u03b5\u03c6\u03c1\u03b9\u03ba\u03ae \u03b4\u03c5\u03c3\u03bb\u03b5\u03b9\u03c4\u03bf\u03c5\u03c1\u03b3\u03af\u03b1 \u03ae \u03b7\u03bb\u03b9\u03ba\u03af\u03b1 \u03ac\u03bd\u03c9 \u03c4\u03c9\u03bd 75 \u03b5\u03c4\u03ce\u03bd. \u03a4\u03b9\u03c4\u03bb\u03bf\u03c0\u03bf\u03b9\u03ae\u03c3\u03c4\u03b5 \u03ba\u03ac\u03b8\u03b5 2-4 \u03b5\u03b2\u03b4\u03bf\u03bc\u03ac\u03b4\u03b5\u03c2 \u03ad\u03c9\u03c2 97\/103 mg \u03b4\u03cd\u03bf \u03c6\u03bf\u03c1\u03ad\u03c2 \u03b7\u03bc\u03b5\u03c1\u03b7\u03c3\u03af\u03c9\u03c2.<\/p>\n \u039a\u03c1\u03af\u03c3\u03b9\u03bc\u03bf\u03c2 \u03ba\u03b1\u03bd\u03cc\u03bd\u03b1\u03c2 \u03b1\u03bb\u03bb\u03b1\u03b3\u03ae\u03c2 \u03b1\u03c0\u03cc \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1 ACE:<\/strong> \u03b5\u03c0\u03b9\u03c4\u03c1\u03ad\u03c8\u03c4\u03b5 \u03bc\u03b9\u03b1 \u03c0\u03b5\u03c1\u03af\u03bf\u03b4\u03bf \u03b5\u03be\u03b1\u03c6\u03ac\u03bd\u03b9\u03c3\u03b7\u03c2 36 \u03c9\u03c1\u03ce\u03bd<\/strong> \u03bc\u03b5\u03c4\u03ac \u03c4\u03b7\u03bd \u03c4\u03b5\u03bb\u03b5\u03c5\u03c4\u03b1\u03af\u03b1 \u03b4\u03cc\u03c3\u03b7 \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1 ACE \u03c0\u03c1\u03b9\u03bd \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03ad\u03bd\u03b1\u03c1\u03be\u03b7 \u03c4\u03bf\u03c5 Vymada \u2014 \u03bf \u03c3\u03c5\u03bd\u03b4\u03c5\u03b1\u03c3\u03bc\u03cc\u03c2 \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1 ACE + \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u03bd\u03b5\u03c6\u03c1\u03b9\u03bb\u03c5\u03c3\u03af\u03bd\u03b7\u03c2 \u03b1\u03c5\u03be\u03ac\u03bd\u03b5\u03b9 \u03c3\u03b7\u03bc\u03b1\u03bd\u03c4\u03b9\u03ba\u03ac \u03c4\u03bf\u03bd \u03ba\u03af\u03bd\u03b4\u03c5\u03bd\u03bf \u03b1\u03b3\u03b3\u03b5\u03b9\u03bf\u03bf\u03b9\u03b4\u03ae\u03bc\u03b1\u03c4\u03bf\u03c2. \u0394\u03b5\u03bd \u03b1\u03c0\u03b1\u03b9\u03c4\u03b5\u03af\u03c4\u03b1\u03b9 \u03c0\u03b5\u03c1\u03af\u03bf\u03b4\u03bf\u03c2 \u03b5\u03be\u03b1\u03c6\u03ac\u03bd\u03b9\u03c3\u03b7\u03c2 \u03b1\u03c0\u03cc ARB.<\/p>\n \u03a0\u03b1\u03c1\u03b1\u03ba\u03bf\u03bb\u03bf\u03cd\u03b8\u03b7\u03c3\u03b7:<\/strong> \u03a0\u03af\u03b5\u03c3\u03b7 \u03b1\u03af\u03bc\u03b1\u03c4\u03bf\u03c2, \u03ba\u03ac\u03bb\u03b9\u03bf, \u03ba\u03c1\u03b5\u03b1\u03c4\u03b9\u03bd\u03af\u03bd\u03b7 \u03c3\u03c4\u03b7 \u03b2\u03b1\u03c3\u03b9\u03ba\u03ae \u03b1\u03be\u03b9\u03bf\u03bb\u03cc\u03b3\u03b7\u03c3\u03b7, \u03c3\u03b5 1-2 \u03b5\u03b2\u03b4\u03bf\u03bc\u03ac\u03b4\u03b5\u03c2 \u03ba\u03b1\u03b9 \u03ba\u03ac\u03b8\u03b5 3-4 \u03bc\u03ae\u03bd\u03b5\u03c2. \u0391\u03bd\u03b1\u03bc\u03ad\u03bd\u03b5\u03c4\u03b1\u03b9 \u03bc\u03b9\u03b1 \u03bc\u03ad\u03c4\u03c1\u03b9\u03b1 \u03b1\u03cd\u03be\u03b7\u03c3\u03b7 \u03c4\u03b7\u03c2 \u03ba\u03c1\u03b5\u03b1\u03c4\u03b9\u03bd\u03af\u03bd\u03b7\u03c2 (\u03c0\u03b1\u03c1\u03cc\u03bc\u03bf\u03b9\u03b1 \u03bc\u03b5 ACEi\/ARB). NT-proBNP \u03b3\u03b9\u03b1 \u03c0\u03b1\u03c1\u03b1\u03ba\u03bf\u03bb\u03bf\u03cd\u03b8\u03b7\u03c3\u03b7 \u03b1\u03c0\u03cc\u03ba\u03c1\u03b9\u03c3\u03b7\u03c2 (\u03c3\u03b7\u03bc\u03b5\u03af\u03c9\u03c3\u03b7: \u03c4\u03bf BNP \u03b4\u03b5\u03bd \u03bc\u03c0\u03bf\u03c1\u03b5\u03af \u03bd\u03b1 \u03c7\u03c1\u03b7\u03c3\u03b9\u03bc\u03bf\u03c0\u03bf\u03b9\u03b7\u03b8\u03b5\u03af \u03b5\u03c0\u03b5\u03b9\u03b4\u03ae \u03b7 \u03bd\u03b5\u03c6\u03c1\u03b9\u03bb\u03c5\u03c3\u03af\u03bd\u03b7 \u03b1\u03c0\u03bf\u03b9\u03ba\u03bf\u03b4\u03bf\u03bc\u03b5\u03af \u03c4\u03bf BNP\u00b7 \u03c7\u03c1\u03b7\u03c3\u03b9\u03bc\u03bf\u03c0\u03bf\u03b9\u03ae\u03c3\u03c4\u03b5 \u03c4\u03bf NT-proBNP \u03c0\u03bf\u03c5 \u03b4\u03b5\u03bd \u03b5\u03af\u03bd\u03b1\u03b9 \u03c5\u03c0\u03cc\u03c3\u03c4\u03c1\u03c9\u03bc\u03b1 \u03bd\u03b5\u03c6\u03c1\u03b9\u03bb\u03c5\u03c3\u03af\u03bd\u03b7\u03c2).<\/p>\n \u03a6\u03c5\u03bb\u03ac\u03be\u03c4\u03b5 \u03c4\u03bf Vymada \u03ba\u03ac\u03c4\u03c9 \u03b1\u03c0\u03cc 25\u00b0C \u03c3\u03c4\u03b7\u03bd \u03b1\u03c1\u03c7\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u03bc\u03b5 \u03c6\u03c5\u03c3\u03b1\u03bb\u03af\u03b4\u03b5\u03c2. \u039a\u03c1\u03b1\u03c4\u03ae\u03c3\u03c4\u03b5 \u03c4\u03bf \u03bc\u03b1\u03ba\u03c1\u03b9\u03ac \u03b1\u03c0\u03cc \u03c0\u03b1\u03b9\u03b4\u03b9\u03ac.<\/p>\n \u039d\u03b1\u03b9 \u2014 \u03c3\u03c4\u03b1\u03bc\u03b1\u03c4\u03ae\u03c3\u03c4\u03b5 \u03c4\u03bf\u03bd \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1 ACE \u03ba\u03b1\u03b9 \u03c0\u03b5\u03c1\u03b9\u03bc\u03ad\u03bd\u03b5\u03c4\u03b5 36 \u03ce\u03c1\u03b5\u03c2 \u03c0\u03c1\u03b9\u03bd \u03be\u03b5\u03ba\u03b9\u03bd\u03ae\u03c3\u03b5\u03c4\u03b5 \u03c4\u03bf Vymada. \u039f \u03c3\u03c5\u03bd\u03b4\u03c5\u03b1\u03c3\u03bc\u03cc\u03c2 \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u03bd\u03b5\u03c6\u03c1\u03b9\u03bb\u03c5\u03c3\u03af\u03bd\u03b7\u03c2 + \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 ACE \u03c0\u03c1\u03bf\u03ba\u03b1\u03bb\u03b5\u03af \u03b1\u03c0\u03b1\u03c1\u03ac\u03b4\u03b5\u03ba\u03c4\u03b1 \u03c0\u03bf\u03c3\u03bf\u03c3\u03c4\u03ac \u03b1\u03b3\u03b3\u03b5\u03b9\u03bf\u03bf\u03af\u03b4\u03b7\u03bc\u03b1 (\u03c4\u03bf \u03bc\u03ac\u03b8\u03b7\u03bc\u03b1 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03b1\u03c0\u03bf\u03c4\u03c5\u03c7\u03b7\u03bc\u03ad\u03bd\u03b7 \u03b4\u03bf\u03ba\u03b9\u03bc\u03ae OVERTURE \u03c4\u03bf\u03c5 omapatrilat). \u0394\u03b5\u03bd \u03b1\u03c0\u03b1\u03b9\u03c4\u03b5\u03af\u03c4\u03b1\u03b9 \u03c0\u03b5\u03c1\u03af\u03bf\u03b4\u03bf\u03c2 \u03b1\u03c0\u03bf\u03c7\u03ae\u03c2 \u03ba\u03b1\u03c4\u03ac \u03c4\u03b7\u03bd \u03b5\u03bd\u03b1\u03bb\u03bb\u03b1\u03b3\u03ae \u03b1\u03c0\u03cc ARB.<\/p>\n \u038c\u03c7\u03b9. \u03a4\u03bf Vymada \u03b1\u03bd\u03c4\u03b9\u03ba\u03b1\u03b8\u03b9\u03c3\u03c4\u03ac \u03c4\u03bf\u03bd \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1 ACE \u03ae \u03c4\u03bf ARB \u03c3\u03c4\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03c4\u03b7\u03c2 \u03ba\u03b1\u03c1\u03b4\u03b9\u03b1\u03ba\u03ae\u03c2 \u03b1\u03bd\u03b5\u03c0\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1\u03c2. \u03a3\u03c5\u03bd\u03b5\u03c7\u03af\u03c3\u03c4\u03b5 \u03c4\u03bf\u03bd \u03b2-\u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1, \u03c4\u03bf\u03bd \u03b1\u03bd\u03c4\u03b1\u03b3\u03c9\u03bd\u03b9\u03c3\u03c4\u03ae \u03c4\u03c9\u03bd \u03bf\u03c1\u03bc\u03bf\u03bd\u03ce\u03bd \u03c4\u03b7\u03c2 \u03c6\u03bb\u03bf\u03b9\u03bf\u03cd \u03c4\u03c9\u03bd \u03b5\u03c0\u03b9\u03bd\u03b5\u03c6\u03c1\u03b9\u03b4\u03af\u03c9\u03bd (\u03c3\u03c0\u03b9\u03c1\u03bf\u03bd\u03bf\u03bb\u03b1\u03ba\u03c4\u03cc\u03bd\u03b7, \u03b5\u03c0\u03bb\u03b5\u03c1\u03b5\u03bd\u03cc\u03bd\u03b7), \u03c4\u03bf\u03bd \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1 SGLT2 \u03ba\u03b1\u03b9 \u03bf\u03c0\u03bf\u03b9\u03b1\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03b4\u03b9\u03bf\u03c5\u03c1\u03b7\u03c4\u03b9\u03ba\u03ac \u03c7\u03c9\u03c1\u03af\u03c2 \u03b1\u03bb\u03bb\u03b1\u03b3\u03ad\u03c2. \u0397 \u03c3\u03cd\u03b3\u03c7\u03c1\u03bf\u03bd\u03b7 \u201c\u03c4\u03b5\u03c4\u03c1\u03b1\u03c0\u03bb\u03ae \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u201d \u03b3\u03b9\u03b1 \u03ba\u03b1\u03c1\u03b4\u03b9\u03b1\u03ba\u03ae \u03b1\u03bd\u03b5\u03c0\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1 \u03bc\u03b5 \u03bc\u03b5\u03b9\u03c9\u03bc\u03ad\u03bd\u03bf \u03ba\u03bb\u03ac\u03c3\u03bc\u03b1 \u03b5\u03be\u03ce\u03b8\u03b7\u03c3\u03b7\u03c2 (HF-REF) \u03b5\u03af\u03bd\u03b1\u03b9: ARNI + \u03b2-\u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1\u03c2 + \u03b1\u03bd\u03c4\u03b1\u03b3\u03c9\u03bd\u03b9\u03c3\u03c4\u03ae\u03c2 MR + \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1\u03c2 SGLT2.<\/p>\n \u0397 \u03bd\u03b5\u03c6\u03c1\u03b9\u03bb\u03c5\u03c3\u03af\u03bd\u03b7 (\u03c4\u03b7\u03bd \u03bf\u03c0\u03bf\u03af\u03b1 \u03b1\u03bd\u03b1\u03c3\u03c4\u03ad\u03bb\u03bb\u03b5\u03b9 \u03c4\u03bf Vymada) \u03b1\u03c0\u03bf\u03b9\u03ba\u03bf\u03b4\u03bf\u03bc\u03b5\u03af \u03c4\u03bf BNP \u03b1\u03bb\u03bb\u03ac \u03cc\u03c7\u03b9 \u03c4\u03bf NT-proBNP. \u039c\u03b5 \u03c4\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 ARNI, \u03c4\u03b1 \u03b5\u03c0\u03af\u03c0\u03b5\u03b4\u03b1 BNP \u03b1\u03c5\u03be\u03ac\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c4\u03b5\u03c7\u03bd\u03b7\u03c4\u03ac (\u03b5\u03c0\u03b5\u03b9\u03b4\u03ae \u03b1\u03c0\u03bf\u03b9\u03ba\u03bf\u03b4\u03bf\u03bc\u03b5\u03af\u03c4\u03b1\u03b9 \u03bb\u03b9\u03b3\u03cc\u03c4\u03b5\u03c1\u03bf), \u03b1\u03c0\u03bf\u03ba\u03c1\u03cd\u03c0\u03c4\u03bf\u03bd\u03c4\u03b1\u03c2 \u03c4\u03b7 \u03bc\u03ad\u03c4\u03c1\u03b7\u03c3\u03b7. \u03a4\u03bf NT-proBNP \u03b5\u03af\u03bd\u03b1\u03b9 \u03ad\u03bd\u03b1 \u03c0\u03c1\u03bf\u03ca\u03cc\u03bd \u03b4\u03b9\u03ac\u03c3\u03c0\u03b1\u03c3\u03b7\u03c2 \u03c0\u03bf\u03c5 \u03b4\u03b5\u03bd \u03b1\u03c0\u03bf\u03c4\u03b5\u03bb\u03b5\u03af \u03c5\u03c0\u03cc\u03c3\u03c4\u03c1\u03c9\u03bc\u03b1 \u03b3\u03b9\u03b1 \u03c4\u03b7 \u03bd\u03b5\u03c6\u03c1\u03b9\u03bb\u03c5\u03c3\u03af\u03bd\u03b7, \u03b5\u03c0\u03bf\u03bc\u03ad\u03bd\u03c9\u03c2 \u03c3\u03c5\u03bd\u03b5\u03c7\u03af\u03b6\u03b5\u03b9 \u03bd\u03b1 \u03b1\u03bd\u03c4\u03b9\u03ba\u03b1\u03c4\u03bf\u03c0\u03c4\u03c1\u03af\u03b6\u03b5\u03b9 \u03c4\u03b7 \u03c3\u03bf\u03b2\u03b1\u03c1\u03cc\u03c4\u03b7\u03c4\u03b1 \u03c4\u03b7\u03c2 \u03ba\u03b1\u03c1\u03b4\u03b9\u03b1\u03ba\u03ae\u03c2 \u03b1\u03bd\u03b5\u03c0\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1\u03c2 \u03ba\u03b1\u03c4\u03ac \u03c4\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 ARNI.<\/p>\n \u038c\u03c7\u03b9 \u2014 \u03c4\u03bf \u03c3\u03c5\u03c3\u03c4\u03b1\u03c4\u03b9\u03ba\u03cc valsartan \u03b5\u03af\u03bd\u03b1\u03b9 \u03c4\u03b5\u03c1\u03b1\u03c4\u03bf\u03b3\u03cc\u03bd\u03bf (\u03bd\u03b5\u03c6\u03c1\u03b9\u03ba\u03ae \u03b1\u03b3\u03ad\u03bd\u03b5\u03b9\u03b1 \u03b5\u03bc\u03b2\u03c1\u03cd\u03bf\u03c5, \u03bf\u03bb\u03b9\u03b3\u03bf\u03c5\u03b4\u03c1\u03ac\u03bc\u03bd\u03b9\u03bf). \u0394\u03b9\u03b1\u03ba\u03cc\u03c8\u03c4\u03b5 \u03c4\u03bf ARNI \u03c0\u03c1\u03b9\u03bd \u03b1\u03c0\u03cc \u03c0\u03c1\u03bf\u03b3\u03c1\u03b1\u03bc\u03bc\u03b1\u03c4\u03b9\u03c3\u03bc\u03ad\u03bd\u03b7 \u03b5\u03b3\u03ba\u03c5\u03bc\u03bf\u03c3\u03cd\u03bd\u03b7 \u03ae \u03ba\u03b1\u03c4\u03ac \u03c4\u03b7\u03bd \u03b5\u03c0\u03b9\u03b2\u03b5\u03b2\u03b1\u03af\u03c9\u03c3\u03b7 \u03bc\u03b7 \u03c0\u03c1\u03bf\u03b3\u03c1\u03b1\u03bc\u03bc\u03b1\u03c4\u03b9\u03c3\u03bc\u03ad\u03bd\u03b7\u03c2 \u03b5\u03b3\u03ba\u03c5\u03bc\u03bf\u03c3\u03cd\u03bd\u03b7\u03c2.<\/p>\n \u039c\u03c0\u03bf\u03c1\u03b5\u03af\u03c4\u03b5 \u03bd\u03b1 \u03b1\u03b3\u03bf\u03c1\u03ac\u03c3\u03b5\u03c4\u03b5 Vymada (sacubitril\/valsartan 50 \u03ba\u03b1\u03b9 100 mg, 28-84 \u03b4\u03b9\u03c3\u03ba\u03af\u03b1) \u03b1\u03c0\u03cc \u03c4\u03bf MedsBase \u03bc\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u03ba\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae.<\/p>\n <\/p>\n \u03a4\u03bf Vymada \u03b5\u03af\u03bd\u03b1\u03b9 \u03c4\u03b1 \u03b4\u03b9\u03c3\u03ba\u03af\u03b1 \u03c3\u03b1\u03ba\u03bf\u03c5\u03bc\u03c0\u03b9\u03c4\u03c1\u03af\u03bb\u03b7\u03c2\/\u03b2\u03b1\u03bb\u03c3\u03b1\u03c1\u03c4\u03ac\u03bd\u03b7\u03c2 50\/100 mg \u03c4\u03b7\u03c2 Novartis \u2014 \u03bf \u03c0\u03c1\u03ce\u03c4\u03bf\u03c2 \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1\u03c2 \u03c5\u03c0\u03bf\u03b4\u03bf\u03c7\u03ad\u03b1 \u03b1\u03b3\u03b3\u03b5\u03b9\u03bf\u03c4\u03b5\u03bd\u03c3\u03af\u03bd\u03b7\u03c2-\u03bd\u03b5\u03c0\u03c1\u03b9\u03bb\u03c5\u03c3\u03af\u03bd\u03b7\u03c2 (ARNI), \u03c0\u03bf\u03c5 \u03c0\u03c9\u03bb\u03b5\u03af\u03c4\u03b1\u03b9 \u03c9\u03c2 Entresto \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2. \u0397 \u03bc\u03b5\u03bb\u03ad\u03c4\u03b7 PARADIGM-HF (2014) \u03ba\u03b1\u03c4\u03ad\u03b3\u03c1\u03b1\u03c8\u03b5 \u03bc\u03b5\u03af\u03c9\u03c3\u03b7 20% \u03c3\u03c4\u03bf\u03bd \u03ba\u03b1\u03c1\u03b4\u03b9\u03b1\u03b3\u03b3\u03b5\u03b9\u03b1\u03ba\u03cc \u03b8\u03ac\u03bd\u03b1\u03c4\u03bf \u03ae \u03bd\u03bf\u03c3\u03b7\u03bb\u03b5\u03af\u03b1 \u03b3\u03b9\u03b1 \u03ba\u03b1\u03c1\u03b4\u03b9\u03b1\u03ba\u03ae \u03b1\u03bd\u03b5\u03c0\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1 \u03c3\u03b5 \u03c3\u03cd\u03b3\u03ba\u03c1\u03b9\u03c3\u03b7 \u03bc\u03b5 \u03c4\u03b7\u03bd \u03b5\u03bd\u03b1\u03bb\u03b1\u03c0\u03c1\u03af\u03bb\u03b7 \u03c3\u03b5 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03bc\u03b5 HF-REF. \u0391\u03bd\u03c4\u03b9\u03ba\u03b1\u03b8\u03b9\u03c3\u03c4\u03ac \u03c0\u03c1\u03ce\u03c4\u03b7\u03c2 \u03b3\u03c1\u03b1\u03bc\u03bc\u03ae\u03c2 \u03c4\u03bf\u03c5\u03c2 \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03b5\u03af\u03c2 ACE\/ARB \u03c3\u03b5 \u03c3\u03c4\u03b1\u03b8\u03b5\u03c1\u03ae HF-REF \u03c3\u03cd\u03bc\u03c6\u03c9\u03bd\u03b1 \u03bc\u03b5 \u03c4\u03b9\u03c2 \u03bf\u03b4\u03b7\u03b3\u03af\u03b5\u03c2 ESC 2021 \u03ba\u03b1\u03b9 AHA\/ACC 2022. \u039a\u03a1\u0399\u03a3\u0399\u039c\u039f: \u0391\u03c0\u03b1\u03b9\u03c4\u03b5\u03af\u03c4\u03b1\u03b9 \u03c0\u03b5\u03c1\u03af\u03bf\u03b4\u03bf\u03c2 \u03b1\u03c0\u03bf\u03c7\u03ae\u03c2 36 \u03c9\u03c1\u03ce\u03bd \u03ba\u03b1\u03c4\u03ac \u03c4\u03b7\u03bd \u03b1\u03bb\u03bb\u03b1\u03b3\u03ae \u03b1\u03c0\u03cc \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1 ACE (\u03ba\u03af\u03bd\u03b4\u03c5\u03bd\u03bf\u03c2 \u03b1\u03b3\u03b3\u03b5\u03b9\u03bf\u03bf\u03af\u03b4\u03b7\u03bc\u03b1). \u03a4\u03bf BNP \u03b4\u03b5\u03bd \u03bc\u03c0\u03bf\u03c1\u03b5\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03ba\u03bf\u03bb\u03bf\u03c5\u03b8\u03ae\u03c3\u03b5\u03b9 \u03c4\u03b7\u03bd \u03b1\u03c0\u03cc\u03ba\u03c1\u03b9\u03c3\u03b7 \u2014 \u03c7\u03c1\u03b7\u03c3\u03b9\u03bc\u03bf\u03c0\u03bf\u03b9\u03ae\u03c3\u03c4\u03b5 NT-proBNP.<\/p>","protected":false},"featured_media":51988,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3260,3356],"product_tag":[3437,3438,3439],"class_list":{"0":"post-51987","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-heart-blood-pressure","9":"product_cat-high-blood-pressure-medication","10":"product_tag-sacubitril","11":"product_tag-valsartan","12":"product_tag-vymada","14":"first","15":"outofstock","16":"shipping-taxable","17":"purchasable","18":"product-type-variable","19":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product\/51987","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/comments?post=51987"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media\/51988"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media?parent=51987"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_brand?post=51987"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_cat?post=51987"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_tag?post=51987"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n
\u03a4\u03b9 \u03b5\u03af\u03bd\u03b1\u03b9 \u03c4\u03bf Vymada;<\/h2>\n
\u03a0\u03ce\u03c2 \u03bb\u03b5\u03b9\u03c4\u03bf\u03c5\u03c1\u03b3\u03b5\u03af \u03bf ARNI<\/h2>\n
\n
\u0391\u03c0\u03bf\u03b4\u03b5\u03b9\u03ba\u03c4\u03b9\u03ba\u03ac \u03a3\u03c4\u03bf\u03b9\u03c7\u03b5\u03af\u03b1<\/h2>\n
\u0395\u03b3\u03ba\u03b5\u03ba\u03c1\u03b9\u03bc\u03ad\u03bd\u03b5\u03c2 \u03a7\u03c1\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n
\n
\u0394\u03bf\u03c3\u03bf\u03bb\u03bf\u03b3\u03af\u03b1<\/h2>\n
\n
\u03a0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n
\n
\u0391\u03bd\u03c4\u03b5\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/h2>\n
\n
\u0391\u03bb\u03bb\u03b7\u03bb\u03b5\u03c0\u03b9\u03b4\u03c1\u03ac\u03c3\u03b5\u03b9\u03c2 \u03a6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd<\/h2>\n
\n
\u0391\u03c0\u03bf\u03b8\u03ae\u03ba\u03b5\u03c5\u03c3\u03b7<\/h2>\n
\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u0395\u03c1\u03c9\u03c4\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n
\u03a0\u03c1\u03ad\u03c0\u03b5\u03b9 \u03bd\u03b1 \u03c3\u03c4\u03b1\u03bc\u03b1\u03c4\u03ae\u03c3\u03c9 \u03c4\u03bf\u03bd \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1 ACE \u03c0\u03c1\u03b9\u03bd \u03b1\u03c0\u03cc \u03c4\u03bf Vymada;<\/h3>\n
\u0398\u03b1 \u03b1\u03bd\u03c4\u03b9\u03ba\u03b1\u03c4\u03b1\u03c3\u03c4\u03ae\u03c3\u03b5\u03b9 \u03c4\u03bf Vymada \u03c4\u03b1 \u03ac\u03bb\u03bb\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03b1 \u03bc\u03bf\u03c5 \u03b3\u03b9\u03b1 \u03ba\u03b1\u03c1\u03b4\u03b9\u03b1\u03ba\u03ae \u03b1\u03bd\u03b5\u03c0\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1;<\/h3>\n
\u0393\u03b9\u03b1\u03c4\u03af \u03bc\u03b5\u03c4\u03c1\u03ac\u03c4\u03b1\u03b9 \u03c4\u03bf NT-proBNP \u03bc\u03bf\u03c5 \u03ba\u03b1\u03b9 \u03cc\u03c7\u03b9 \u03c4\u03bf BNP;<\/h3>\n
\u039c\u03c0\u03bf\u03c1\u03ce \u03bd\u03b1 \u03c0\u03ac\u03c1\u03c9 Vymada \u03ba\u03b1\u03c4\u03ac \u03c4\u03b7\u03bd \u03b5\u03b3\u03ba\u03c5\u03bc\u03bf\u03c3\u03cd\u03bd\u03b7;<\/h3>\n
\u03a0\u03bf\u03cd \u03bc\u03c0\u03bf\u03c1\u03ce \u03bd\u03b1 \u03b1\u03b3\u03bf\u03c1\u03ac\u03c3\u03c9 Vymada online;<\/h3>\n
\u03a3\u03c7\u03b5\u03c4\u03b9\u03ba\u03ac \u039a\u03b1\u03c1\u03b4\u03b9\u03b1\u03b3\u03b3\u03b5\u03b9\u03b1\u03ba\u03ac \u03a6\u03ac\u03c1\u03bc\u03b1\u03ba\u03b1<\/h2>\n
\n